GlassScriptPhysician profile
Sharma L Bishop
NPI 1538464235
$2,553.74
in general payments reported to CMS, 2019-2025
32 companies · $47.80 in 2025
The $47.80 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $224 · 2020: $930 · 2021: $563 · 2022: $505 · 2023: $121 · 2024: $163 · 2025: $47.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $332.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $440.36 | 2019-2025 | |
| Glaxosmithkline, LLC. | $352.97 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $278.23 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $151.87 | 2019-2022 | |
| Pfizer INC. | $141.98 | 2019-2024 | |
| Lilly USA, LLC | $129.60 | 2020-2023 | Mounjaro |
| Corcept Therapeutics | $124.01 | 2022-2023 | Korlym |
| Amgen INC. | $89.00 | 2021-2023 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $88.23 | 2020-2024 | Breztri |
| Merck Sharp & Dohme LLC | $78.83 | 2020-2021 | |
| Amarin Pharma, INC. | $75.23 | 2020-2021 | |
| Novo Nordisk INC | $65.17 | 2021-2024 | Ozempic |
| Daiichi Sankyo INC. | $64.68 | 2020 | |
| Novartis Pharmaceuticals Corporation | $48.23 | 2019-2021 | |
| Pharming Healthcare, INC. | $42.76 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $37.98 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.32 | 2019-2023 | Xifaxan |
| Gilead Sciences, INC. | $32.85 | 2020-2021 | |
| Biocryst US Sales Co., LLC | $29.95 | 2022 | |
| Almatica Pharma LLC | $26.97 | 2021 | |
| Horizon Therapeutics Plc | $24.62 | 2020 | |
| Allergan, INC. | $23.27 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $22.94 | 2022 | |
| Nestle Healthcare Nutrition INC. | $19.88 | 2021 | |
| Boston Scientific Corporation | $19.42 | 2022 | |
| Intercept Pharmaceuticals, INC. | $18.73 | 2020 | |
| Scilex Pharmaceuticals INC. | $17.41 | 2022 | |
| Mylan Specialty L.P. | $16.20 | 2021 | |
| Medtronic, INC. | $15.89 | 2024 | Minimed 780g |
| Sanofi Pasteur INC. | $15.66 | 2019 | |
| Abbott Laboratories | $13.98 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharma Bishop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.